Bernstein analyst Justin Smith upgraded Argenx (ARGX) to Outperform from Market Perform with a EUR 755 price target The firm is increasing its 2030 group sales forecast by over 100% to $11B, which implies that key growth driver Vyvgart will become the 4th largest autoimmune drug ever. But this new 2030 risk adjusted group sales estimate equates to 30k treated patients for a share of 6%. Bernstein says its analysis also suggests that the risks to the s/p are strongly skewed to the upside.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se: Buy Rating Backed by Vyvgart’s Robust Launch and Promising Pipeline
- Argenx upgraded to Hold from Sell at Deutsche Bank
- Argenx price target raised to $1,100 from $775 at Guggenheim
- Argenx’s Promising Growth: Buy Rating Backed by Strong Pipeline and Innovative Developments
- Argenx announces Vyvgart, Vyvgart Hytrulo data